Overview

A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants

Status:
Completed

Trial end date:
2017-05-19

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the pharmacokinetic (PK) and safety of darunavir (DRV) and cobicistat (COBI) after a single oral administration of Prezcobix (DRV/COBI fixed-dose combination tablet) in healthy Japanese adult participants.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Cobicistat
Darunavir